Fed. Circ. Was Right To Deny Amgen IP 'Gambit,' Justices Told
Sanofi and Regeneron on Monday urged the U.S. Supreme Court to turn away Amgen's petition regarding when antibody-based patents are enabled, saying Amgen's bid to overly expand its patent rights over...To view the full article, register now.
Already a subscriber? Click here to view full article